FDA Greenlights Novartis' First-in-Class Therapy for CML - BioSpace
FDA approved Novartis’ Scemblix for treating chronic myeloid leukemia (CML) in adults with specific conditions, including resistance or intolerance to TKIs. Scemblix, a STAMP inhibitor, targets the ABL myristoyl pocket, showing promise in clinical trials with fewer adverse reactions compared to Bosulif. It's now available in the U.S. for qualified patients.
Reference News
FDA Greenlights Novartis' First-in-Class Therapy for CML - BioSpace
FDA approved Novartis’ Scemblix for treating chronic myeloid leukemia (CML) in adults with specific conditions, including resistance or intolerance to TKIs. Scemblix, a STAMP inhibitor, targets the ABL myristoyl pocket, showing promise in clinical trials with fewer adverse reactions compared to Bosulif. It's now available in the U.S. for qualified patients.